The Relevance Between the Level of Fetal Hemoglobin and Short-term Complications in Extremely Preterm Infants

March 15, 2023 updated by: The First Hospital of Jilin University
A monocentric prospective study was conducted to find the relevance between the level of fetal hemoglobin and short-term complications in extremely preterm infants

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Anticipated)

92

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Jilin
      • Chang chun, Jilin, China, 130000
        • First Hospital of Jilin University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 day to 2 months (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Preterm infants with gestational age <32 weeks or birth weight <1500g

Description

Inclusion Criteria:

  1. Preterm infants with gestational age <32 weeks or birth weight <1500g
  2. Parents agree to attend

Exclusion Criteria:

  1. serious functional or organic diseases
  2. severe congenital deformity
  3. parents reject to attend

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Experimental group
Incorporate blood gas analysis indicators in D1-D7, after birth,1 week before and on the day of onset of early complications
Control group
Incorporate blood gas analysis indicators in D1-D7,D14,D28after birth and the day of diacharge

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Occurrence and severity of early complications in premature infants
Time Frame: 2022.1-2023.1
include necrotizing enterocolitis,bronchopulmonary dysplasia,retinopathy, Intraventricular hemorrhage above degree Ⅱ,leukomalacia,late-onset sepsis
2022.1-2023.1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The First Hospital of Jilin University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

April 1, 2023

Primary Completion (Anticipated)

February 18, 2024

Study Completion (Anticipated)

May 30, 2024

Study Registration Dates

First Submitted

March 15, 2023

First Submitted That Met QC Criteria

March 15, 2023

First Posted (Actual)

March 29, 2023

Study Record Updates

Last Update Posted (Actual)

March 29, 2023

Last Update Submitted That Met QC Criteria

March 15, 2023

Last Verified

June 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • wu hui

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Fetal Hemoglobin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe